User profiles for "author:J Creaney"
Jenette CreaneyUniversity of Western Australia Verified email at uwa.edu.au Cited by 32705 |
[HTML][HTML] Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis
Purpose Mesothelin is currently considered the best available serum biomarker of malignant
pleural mesothelioma. To examine the diagnostic accuracy and use of serum mesothelin in …
pleural mesothelioma. To examine the diagnostic accuracy and use of serum mesothelin in …
Guidelines for the Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant MesotheliomaComplementary Statement from the International Mesothelioma …
…, V Ascoli, CWM Bedrossian, ME Boon, J Creaney… - Acta cytologica, 2015 - karger.com
Objective: To provide practical guidelines for the cytopathologic diagnosis of malignant
mesothelioma. Data Sources: Cytopathologists with an interest in the field involved in the …
mesothelioma. Data Sources: Cytopathologists with an interest in the field involved in the …
Integrative molecular characterization of malignant pleural mesothelioma
…, DJ Kwiatkowski, R Bueno, AS Tsao, J Creaney… - Cancer discovery, 2018 - AACR
Malignant pleural mesothelioma (MPM) is a highly lethal cancer of the lining of the chest
cavity. To expand our understanding of MPM, we conducted a comprehensive integrated …
cavity. To expand our understanding of MPM, we conducted a comprehensive integrated …
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21. 1 losses in malignant pleural mesothelioma
Malignant pleural mesotheliomas (MPMs) often show CDKN2A and NF2 inactivation, but
other highly recurrent mutations have not been described. To identify additional driver …
other highly recurrent mutations have not been described. To identify additional driver …
Mesothelin-family proteins and diagnosis of mesothelioma
Background Mesothelioma is a highly aggressive tumour for which there are no reliable
serum tumour markers. Identification of such a marker would be useful in diagnosis of …
serum tumour markers. Identification of such a marker would be useful in diagnosis of …
[HTML][HTML] Malignant mesothelioma biomarkers: from discovery to use in clinical practice for diagnosis, monitoring, screening, and treatment
J Creaney, BWS Robinson - Chest, 2017 - Elsevier
Malignant pleural mesothelioma is a highly aggressive tumor associated with asbestos
exposure. There are few effective treatment options for mesothelioma, and patients have a …
exposure. There are few effective treatment options for mesothelioma, and patients have a …
Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
J Creaney, IM Dick, TM Meniawy, SL Leong, JS Leon… - Thorax, 2014 - thorax.bmj.com
Background Pleural malignant mesothelioma (MM) is a deadly tumour predominantly
associated with asbestos exposure. A reliable diagnostic and prognostic marker for MM will …
associated with asbestos exposure. A reliable diagnostic and prognostic marker for MM will …
[HTML][HTML] A novel clinical prediction model for prognosis in malignant pleural mesothelioma using decision tree analysis
…, I Duffus, D de Fonseka, A Segal, J Creaney… - Journal of Thoracic …, 2016 - Elsevier
Introduction Malignant pleural mesothelioma (MPM) is a rare cancer with a heterogeneous
prognosis. Prognostic models are not widely utilized clinically. Classification and regression …
prognosis. Prognostic models are not widely utilized clinically. Classification and regression …
[HTML][HTML] Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma
…, YY Cheng, B Badrian, SC Kao, J Creaney… - Journal of thoracic …, 2012 - Elsevier
Introduction: We investigated the ability of cell-free microRNAs (miRNAs) in plasma and
serum to serve as a biomarker for malignant mesothelioma (MM). Methods: Using miRNA …
serum to serve as a biomarker for malignant mesothelioma (MM). Methods: Using miRNA …
A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit
Aims: Cytological diagnosis of malignant pleural mesothelioma (MPM) is controversial, but
has been used in our institution for over 30 years. To assess the role of effusion cytology in …
has been used in our institution for over 30 years. To assess the role of effusion cytology in …